[Featured Stocks] Chong Kun Dang Group Shares Rise on Hopes for Domestic No.2 COVID-19 Treatment
[Asia Economy Reporter Park Jihwan] On the 17th, stocks of the Chong Kun Dang Group are showing strong performance in the domestic stock market amid expectations for the approval of the second domestically produced COVID-19 treatment.
As of 9:40 AM today, the stock price of Chong Kun Dang Bio is trading at 69,900 KRW, up 8.71% (6,000 KRW) from the previous trading day.
Chong Kun Dang (5.07%) and Chong Kun Dang Holdings (1.37%) are also on the rise.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The rise in Chong Kun Dang Group stocks is interpreted as a positive factor for investor sentiment following the news that the COVID-19 treatment 'Napabeltan,' developed by Chong Kun Dang, has completed Phase 2 clinical trials. On the 8th, Chong Kun Dang applied to the Ministry of Food and Drug Safety for conditional approval of the COVID-19 treatment based on the Phase 2 clinical trial results of Napabeltan.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
